Literature DB >> 22951518

Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice.

Vasco Filipe1, Wim Jiskoot, Abdul Hafid Basmeleh, Andhyk Halim, Huub Schellekens, Vera Brinks.   

Abstract

The presence of protein aggregates in biopharmaceutical formulations is of great concern for safety and efficacy reasons. The aim of this study was to correlate the type and amount of IgG monoclonal antibody aggregates with their immunogenic potential. IgG degradation was obtained by freeze-thawing cycles, pH-shift cycles, heating, shaking and metal-catalyzed oxidation. The size, amount, morphology and type of intermolecular bonds of aggregates, as well as structural changes and epitope integrity were characterized. These formulations were injected in mice transgenic (TG) for human genes for Ig heavy and light chains and their non-transgenic (NTG) counterparts. Anti-drug antibody (ADA) titers were determined by bridging ELISA. Both unstressed IgG and freeze-thawed formulation did not induce measurable ADA levels. A mild antibody response was obtained in a fairly small percentage of mice, when injected with shaken, pH-shifted and heated formulations. The metal-catalyzed oxidized IgG formulation was the most immunogenic one, in both ADA titers and number of responders. The overall titers of NTG responders were significantly higher than the ones produced by TG mice, whereas there was no significant difference between the overall number of TG and NTG responders. This study reinforces the important role of protein aggregates on immunogenicity of therapeutic proteins and provides new insight into the immunogenic potential of different types of IgG aggregates. The results indicate that the quality of the IgG aggregates has more impact on the development of an immune response than their quantity or size.

Entities:  

Keywords:  IgG; accelerated stress conditions; immunogenicity; protein aggregates; transgenic mice

Mesh:

Substances:

Year:  2012        PMID: 22951518      PMCID: PMC3502241          DOI: 10.4161/mabs.22066

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  51 in total

1.  The dependence of the scattering of light on angle and concentration in linear polymer solutions.

Authors:  B H ZIMM
Journal:  J Phys Colloid Chem       Date:  1948-01

Review 2.  Protein aggregation: pathways, induction factors and analysis.

Authors:  Hanns-Christian Mahler; Wolfgang Friess; Ulla Grauschopf; Sylvia Kiese
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

3.  Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation.

Authors:  Klaus Wuchner; Jochen Büchler; Rene Spycher; Paul Dalmonte; David B Volkin
Journal:  J Pharm Sci       Date:  2010-08       Impact factor: 3.534

4.  Taylor dispersion analysis compared to dynamic light scattering for the size analysis of therapeutic peptides and proteins and their aggregates.

Authors:  Andrea Hawe; Wendy L Hulse; Wim Jiskoot; Robert T Forbes
Journal:  Pharm Res       Date:  2011-05-11       Impact factor: 4.200

5.  Circular dichroic spectra of L-cystine and its dihydrochloride crystals in KBr disc in relation to the circular dichroism of disulfide bonds in proteins.

Authors:  A Imanishi; T Isemura
Journal:  J Biochem       Date:  1969-02       Impact factor: 3.387

6.  Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates.

Authors:  Vasco Filipe; Andrea Hawe; Wim Jiskoot
Journal:  Pharm Res       Date:  2010-03-04       Impact factor: 4.200

7.  Immunologic responses of graft recipients to antilymphocyte globulin: effect of prior treatment with aggregate-free gamma globulin.

Authors:  M E Weksler; G Bull; G H Schwartz; K H Stenzel; A L Rubin
Journal:  J Clin Invest       Date:  1970-08       Impact factor: 14.808

8.  Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality.

Authors:  John F Carpenter; Theodore W Randolph; Wim Jiskoot; Daan J A Crommelin; C Russell Middaugh; Gerhard Winter; Ying-Xin Fan; Susan Kirshner; Daniela Verthelyi; Steven Kozlowski; Kathleen A Clouse; Patrick G Swann; Amy Rosenberg; Barry Cherney
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

9.  Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta.

Authors:  Miranda M C van Beers; Melody Sauerborn; Francesca Gilli; Suzanne Hermeling; Vera Brinks; Huub Schellekens; Wim Jiskoot
Journal:  J Immunol Methods       Date:  2009-10-24       Impact factor: 2.303

10.  Comparison of the immune responsiveness of NZB and NZB X NZW F1 hybrid mice with that of other strains of mice.

Authors:  J C Cerottini; P H Lambert; F J Dixon
Journal:  J Exp Med       Date:  1969-11-01       Impact factor: 14.307

View more
  37 in total

1.  In vivo fluorescence imaging of IgG1 aggregates after subcutaneous and intravenous injection in mice.

Authors:  Vasco Filipe; Ivo Que; John F Carpenter; Clemens Löwik; Wim Jiskoot
Journal:  Pharm Res       Date:  2013-08-15       Impact factor: 4.200

Review 2.  Oxidation of therapeutic proteins and peptides: structural and biological consequences.

Authors:  Riccardo Torosantucci; Christian Schöneich; Wim Jiskoot
Journal:  Pharm Res       Date:  2013-09-25       Impact factor: 4.200

3.  Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions.

Authors:  Srivalli N Telikepalli; Ozan S Kumru; Cavan Kalonia; Reza Esfandiary; Sangeeta B Joshi; C Russell Middaugh; David B Volkin
Journal:  J Pharm Sci       Date:  2014-01-22       Impact factor: 3.534

4.  Radar chart array analysis to visualize effects of formulation variables on IgG1 particle formation as measured by multiple analytical techniques.

Authors:  Cavan Kalonia; Ozan S Kumru; Jae Hyun Kim; C Russell Middaugh; David B Volkin
Journal:  J Pharm Sci       Date:  2013-10-09       Impact factor: 3.534

5.  Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics.

Authors:  Maryam Ahmadi; Christine J Bryson; Edward A Cloake; Katie Welch; Vasco Filipe; Stefan Romeijn; Andrea Hawe; Wim Jiskoot; Matthew P Baker; Mark H Fogg
Journal:  Pharm Res       Date:  2015-04       Impact factor: 4.200

6.  Biosimilarity under stress: A forced degradation study of Remicade® and Remsima™.

Authors:  Karthik Pisupati; Alexander Benet; Yuwei Tian; Solomon Okbazghi; Jukyung Kang; Michael Ford; Sergei Saveliev; K Ilker Sen; Eric Carlson; Thomas J Tolbert; Brandon T Ruotolo; Steven P Schwendeman; Anna Schwendeman
Journal:  MAbs       Date:  2017-08-08       Impact factor: 5.857

7.  The immunogenicity of antibody aggregates in a novel transgenic mouse model.

Authors:  Juliana Bessa; Sabine Boeckle; Hermann Beck; Thomas Buckel; Sonja Schlicht; Martin Ebeling; Anna Kiialainen; Atanas Koulov; Björn Boll; Thomas Weiser; Thomas Singer; Antonius G Rolink; Antonio Iglesias
Journal:  Pharm Res       Date:  2015-01-29       Impact factor: 4.200

Review 8.  Preclinical models used for immunogenicity prediction of therapeutic proteins.

Authors:  Vera Brinks; Daniel Weinbuch; Matthew Baker; Yann Dean; Philippe Stas; Stefan Kostense; Bonita Rup; Wim Jiskoot
Journal:  Pharm Res       Date:  2013-05-07       Impact factor: 4.200

9.  Probing structurally altered and aggregated states of therapeutically relevant proteins using GroEL coupled to bio-layer interferometry.

Authors:  Subhashchandra Naik; Ozan S Kumru; Melissa Cullom; Srivalli N Telikepalli; Elizabeth Lindboe; Taylor L Roop; Sangeeta B Joshi; Divya Amin; Phillip Gao; C Russell Middaugh; David B Volkin; Mark T Fisher
Journal:  Protein Sci       Date:  2014-07-28       Impact factor: 6.725

10.  Identification of oxidation sites and covalent cross-links in metal catalyzed oxidized interferon Beta-1a: potential implications for protein aggregation and immunogenicity.

Authors:  Riccardo Torosantucci; Victor S Sharov; Miranda van Beers; Vera Brinks; Christian Schöneich; Wim Jiskoot
Journal:  Mol Pharm       Date:  2013-05-02       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.